Clinical image: hidden costs of anti-tumor necrosis factor alpha therapy

Arthritis Rheum. 2003 Mar;48(3):868. doi: 10.1002/art.10874.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / economics*
  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents / economics*
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / economics*
  • Cost-Benefit Analysis
  • Epoxy Resins
  • Humans
  • Infliximab
  • Male
  • Middle Aged
  • Phthalic Anhydrides
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / economics*
  • Tumor Necrosis Factor-alpha / therapeutic use
  • Wit and Humor as Topic*

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Epoxy Resins
  • Phthalic Anhydrides
  • Tumor Necrosis Factor-alpha
  • araldite
  • Infliximab